Steven A. Carr
Institute of MIT and Harvard, Boston, MA, USA
A new era of quantitative biology enabled by mass spectrometry based proteomic technologies has arrived. We can now define the content, relative abundance, modification states and interaction partners of proteins in a dynamic and temporal manner on a near-global basis in organelles, whole cells and clinical samples, providing information of unprecedented detail. At the Broad Institute we are developing and applying these technologies in a wide array of studies including defining the subcellular locations of proteins in health and disease, connecting cancer genotype to molecular phenotype, unraveling the basis of the innate-immune response, identifying the mechanism of action of drug-like molecules and to discover and verify protein biomarkers of disease. I will present the results of several recent studies that convey a sense of the breadth and depth of application of modern proteomics to biology and medicine.